Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer

Bibliography

• NOGALES E: Structural insight into microtubule function. Ann. Rev Biophys. Biomol Struct. (2001) 30:397–420.
   PubMedGoogle Scholar
• ••A good review of microtubule structure andfunction.
   Google Scholar
• LOWE J, LI H, DOWNING KH, NOGALES E: Refined structure of 4- tubulin at 3.5 A resolution.Biol. (2001) 313:1045–1057.
   PubMed Web of Science ®Google Scholar
• FORD HJ, PARDEE AB: Cancer and cell cycle.Biochem. (1999) 32/33(Suppl.):166–172.
   Google Scholar
• •A concise review of mammalian somatic cell cycle events and their control.
   Google Scholar
• JORDAN MA, WILSON L: Use of drugs to study role of microtubule assembly dynamics in living cells. In: Methods in Enzymology Vallee R (Ed.), Academic Press, London (1998) 298:252–276.
   PubMedGoogle Scholar
• ••A good review covering the current state ofknowledge regarding the binding of antimitotic agents to tubulin and miroctubules.
   Google Scholar
• DOWNING KH: Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Ann. Rev Cell. Dev. Biology (2000) 16:89–111.
   PubMed Web of Science ®Google Scholar
• ••A good review of the structure of thetubulin heterodimer and the binding sites of antimitotic agents.
   Google Scholar
• TRAXLER P, BOLD G, BUCHDUNGER E et al: Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev (2001) 21:499–512.
   PubMed Web of Science ®Google Scholar
• BASELGA J, AVERBUCH SD: ZD1839 ('Iressa') as an anticancer agent. Drugs (2000) 60 (supp1.1):33–40.
   Google Scholar
• DUMONTET C: Mechanisms of action and resistance to tubulin-binding agents. Exp. Opin. Invest. Drugs (2000) 9:779–788.
   PubMed Web of Science ®Google Scholar
• •A review of all possible mechanisms of resistance to antimitotic agents.
   Google Scholar
• BURKHART CA, KAVALLARIS M, BAND HORWITZ S: The role of 13-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta (2001) 1471:1–9.
   PubMed Web of Science ®Google Scholar
• LI Q, SHAM HL, ROSENBERG SH: Antimitotic agents. Ann. Rep. Med. Chem. (1999) 34:139–148.
   Google Scholar
• ••A concise review of antirntitotic agentsbefore 1999.
   Google Scholar
• VON ANGERER E: New inhibitors of tubulin polymerisation. Exp. Opin. The]: Patents (1999) 9:1069–1081.
   Web of Science ®Google Scholar
• A good review of tubulin polymerisation inhibitors in the patent literature before 1999.
   Google Scholar
• LEE KH: Novel antitumor agents from higher plants. Med. Res. Rev (1999) 19:569–596.
   PubMed Web of Science ®Google Scholar
• LEE KH: Anticancer drug design based on plant-derived natural products. I Biomed. ScL (1999) 6:236–250.
   PubMed Web of Science ®Google Scholar
• NISHIO K, SAIJO N: Cytoskeletons and antimitotic agents developed in Japan. Anticancer Drug Des. (1999) 14:133–141.
   PubMedGoogle Scholar
• SHI Q, CHEN K, MORRISNATSCHKE SL, LEE KH: Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Carr. Pharm. Des. (1998) 4:219–248.
   PubMed Web of Science ®Google Scholar
• ••A review of antimtitotic agents before 1998.
   Google Scholar
• IWASAKI S: Natural organic compounds that affect microtubule functions. Pharm. Soc. fpn. (1998) 118:111–126.
   Google Scholar
• JORDAN A, HADFIELD JA, LAWRENCE NJ, MCGOWN AT: Tubulin as a target for anticancer drugs - agents which interact with the mitotic spindle. Med. Res. Rev (1998) 18:259–296.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of antimitoticagents before 1998.
   Google Scholar
• GUHA S, BHATTACHARYYA B: The colchicine-tubulin interaction - a review. Carr. Sci. (1997) 73:351–358.
   Google Scholar
• BAI R, COVELL DG, PEI XF et al: Mapping the binding site of colchicinoids on I3-tubulin. 2-Chloroacety1-2-demethylthiocolchicine covalently reacts predominantly with cysteine 239 and secondarily with cysteine 354. j. Biol. Chem. (2000) 275:40443–40452.
   Google Scholar
• JANIK ME, BANE SL: Synthesis and antimicrotubule activity of combretatropone derivatives. Bioorg. Med. Chem. (2002) 10:1895–1903.
   PubMedGoogle Scholar
• GUAN J, ZHU XK, TACHIBANA Y et al: Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogues as novel topoisomerase II inhibitors. j. Med. Chem. (1998) 41:1956–1961.
   Google Scholar
• GELMI ML, MOTTADELLI S, POCAR D et al.: Ndeacetyl-Naminoacykhiocolchicine derivatives: synthesis and biological evaluation on MDR-positive and MDR-negative human cancer cell lines. Med. Chem. (1999) 42:5272–5276.
   Google Scholar
• MILLER TA, BULMAN AL, THOMPSON CD, MACDONALD TL: The synthesis and evaluation of temperature sensitive tubulin toxins. Bioorg. Med. Chem. Lett. (1999) 9:407–412.
   PubMedGoogle Scholar
• BRECHT R, SEITZ G, GUENARD D, THORET S: Novel allocolchicinoids with an eight membered B ring: design, synthesis and inhibition of tubulin assembly. Bioorg. Med. Chem. (2000) 8:557–562.
   PubMedGoogle Scholar
• GUAN J, ZHU XK, BROSSI A et al.: Antitumor agents. 192. Antitubulin effect and cytotoxicity of C(7)-oxygenated allocolchicinoids. Coll. Czech. Chem. Comm. (1999) 64:217–228.
   Google Scholar
• DAVIS PD, HILL SA, GALBRAITH SM et al: ZD6126: A new agent causing selective damage of tumour vasculature. 9Ist Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000). Abstract 2085.
   Google Scholar
• DAVIS PD, HILL SA, CHAPLIN DJ, BLAKEY DC: Comparison of the anti-tumour activity of ZD6126 administered by different routes. 92nd Annual Meeting of American Association for Cancer Research. New Orleanes, USA (2001): Abstract 4419.
   Google Scholar
• BLAKEY DC, ASHTON SE, EARDLEY SE et al.: ZD6126: a novel vascular targeting agent which causes massive necrosis in a range of human tumour xenograft model. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 2086.
   Google Scholar
• ••ZD6126 antivascular activity and a goodlist of available tools and models to evaluate antivascular activity.
   Google Scholar
• GOTO H, YANO S, ZHANG H et al: Activity of a new vascular-targeting agent, CD6126, in pulmonary metastases from human lung adenocarcinoma in nude mice. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 777.
   Google Scholar
• BLAKEY DC, WESTWOOD FR, ASHTON SE: Vascular targeting activity of ZD6126 in two tumour models growing in athymic rats. 92nd Annual Meeting of American Association for Cancer Research. New Orleans, USA (2001): Abstract 4421.
   Google Scholar
• EVELHOCH JL, HE Z, POLIN L et al: MRI evaluation of the effects of ZD6126 on tumor vasculture. 92nd Annual Meeting of American Association for Cancer Research. New Orleans, USA (2001): Abstract 580.
   Google Scholar
• BLAKEY DC, ASHTON SE, WESTWOOD FR, RYAN A: Optimisation of ZD6126 activity in the Galu-6 tumor model. 93rd Annual Meeting of American Association for Cancer Research San Francisco, USA (2002): Abstract 778.
   Google Scholar
• SIEMANN DW, LEPLER S, ROJIANI A: The novel vascular-targeting agent ZD6126 enhances the anti-tumor efficacy of cisplatin. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 2594.
   Google Scholar
• WEDGE SR, KENDREW J, OGILVIE DJ et al.: Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced antitumor response. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 5351.
   Google Scholar
• ARNOULD JC, BIRD TG, ASHTON SE, BLAKEY DC, DAVIS PD: Novel vascular targeting agents: amino colchicinol derivatives of ZD6126. 92nd Annual Meeting of American Association for Cancer Research. New Orleans, USA (2001): Abstract 4426.
   Google Scholar
• XIA Y, YANG ZY, XIA P et al: Antitumor agents - 181 - synthesis and biological evaluation of 6,7,2, 3',4'-substituted-1, 2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents. Med. Chem (1998) 41:1155–1162.
   Google Scholar
• GRIGGS J, METCALFE JC, HESKETH R: Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol (2001) 2:82–87.
   PubMed Web of Science ®Google Scholar
• ••A concise review of antivascular activityCA-4P.
   Google Scholar
• OHSUMI K, NAKAGAWA R, FUKUDA Y et al.: Novel combretastatin analogues effective against murine solid tumors - design and structure-activity relationships.j Med. Chem. (1998) 41:3022–3032.
   PubMed Web of Science ®Google Scholar
• •SAR of AC-7739 series.
   Google Scholar
• TOZER GM, PRISE VE, WILSON J et al: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. (1999) 59:1626–1634.
   PubMed Web of Science ®Google Scholar
• TOZER GM, PRISE VE, WILSON J et al: Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. (2001) 61:6413–6422.
   PubMed Web of Science ®Google Scholar
• BEAUREGARD DA, HILL SA, CHAPLIN DJ, BRINDLE KM: The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res. (2001) 61:6811–6815.
   PubMed Web of Science ®Google Scholar
• IWASAKI S, SHIRAI R: Natural organic compounds that affect microtubule functions: syntheses and structure-activity relationships of combretastatins, curacin A and their analogs as the colchicine-site ligands on tubulin. I Pharm. Soc. fpn (2000) 120:875–889.
   PubMedGoogle Scholar
• LIN CM, SINGH SB, CHU PS et al.: Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mot. Pharmacol (1988) 34:200–208.
   PubMed Web of Science ®Google Scholar
• MAYA AB, DEL REY B, LAMAMIE DE CLAIRAC RP et al.: Design, synthesis and cytotoxic activities of naphthyl analogues of combretastatin A-4. Bioorg. Med. Chem. Lett. (2000) 10:2549–2551.
   Google Scholar
• HADFIELD JA, MCGOWN AT: Preparation and evaluation of diarylalkynes as antitumour agents. Synth. Commun. (1998) 28:1421–1431.
   Web of Science ®Google Scholar
• PETTIT GR, LIPPERT JW III: Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anti-Cancer Drug Des. (2000) 15:203–216.
   PubMedGoogle Scholar
• PETTIT GR, MINARDI MD, BOYD MR, PETTIT RK: Antineoplastic agents 463. Synthesis of combretastatin A-3 diphosphate prodrugs. Anti-Cancer Drug Des. (2000) 15:397–403.
   PubMedGoogle Scholar
• HOLWELL SE, COOPER PA, GROSIOS K et al: Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res. (2002) 22:707–711.
   PubMed Web of Science ®Google Scholar
• PINNEY KG, TANPURE RP: Triarylethylene ligands which incorporate structural motifs reminiscent of combretastatin A-4 and tammdfan: synthesis and biological evaluation as tubulin binding compounds. 222nd ACS Meeting. Chicago, USA (2001): MEDI68.
   Google Scholar
• OHSUMI K, HATANAKA T, NAKAGAWA R et al.: Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins. Anti-Cancer Drug Des. (1999) 14:539-548. Si.NIHEI Y, SUGA Y, MORINAGA Y et al: A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. jpn. Cancer Res. (1999) 90:1016–1025.
   Google Scholar
• NIHEI Y, SUZUKI M, OKANO A et al: Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. fpn. I Cancer Res (1999) 90:1387–1395.
   Google Scholar
• •In vivo antivascular activity of AC-7739 and side by side comparison with AC-7739, CA4P, colchicine, vinblastine, and E7010.
   Google Scholar
• HORI K, SAITO S, SATO Y, KUBOTA K: Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med. Sci. Monitor (2001) 7:26–33.
   PubMedGoogle Scholar
• HORI K, SAITO S, NIHEI Y, SUZUKI M, SATO Y: Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. fpn..1. Cancer Res. (1999) 90:1026–1038.
   PubMedGoogle Scholar
• ARCHIMBAUD Y, FRASCHINI MC et al.: Mouse plasma and tumour pharmacokinetics of AVE8062, a new combretastatin. 93rd Annual Meeting of American Association for Cancer Research San Francisco, USA (2002): Abstract 779.
   Google Scholar
• BISSERY MC, LEJEUNE P, VRIGNAUD P: ha vivo evaluation of AVE8062A, a compound active on the tumor vasculature. 93rd Annual Meeting of American Association for Cancer Research San Francisco, USA (2002): Abstract 780.
   Google Scholar
• LEJEUNE P, HODGE TG, VRIGNAUD P, BISSERY MC: ha vivo antitumor activity and tumor necrosis induced by AVE8062A, a tumor vasculature targeting agent. 93rd Annual Meeting of American Association for Cancer Research San Francisco, USA (2002): Abstract 781.
   Google Scholar
• HATANAKA T, FUJITA K, OHSUMI K et al.: Novel B ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg. Med. Chem. Lett. (1998) 8:3371–3374.
   PubMedGoogle Scholar
• PETTIT GR, TOKI BE, HERALD DL et al.: Antineoplastic agents. 410. Asymmetric hydroxylation of trans- combretastatinJ. Med. Chem. (1999)42:1459–1465.
   Google Scholar
• PETTIT GR, LIPPERT JW III, HERALD DL, HAMEL E, PETTIT RK: Antineoplastic agents 440. Asymmetric synthesis and evaluation of the combretastatin A-1 SAR probes (1S,23)- and (1R,2/0-1, dihydroxy- 1-(2',3'-dihydroxy-4'-methoxypheny1)-2-(3' ',4' ',5' '-trimethoxypheny1)-ethane. J. Nat. Prod. (2000) 63:969–974.
   Google Scholar
• SHIRAI R, TAKAYAMA H, NISHIKAWA A, KOISO Y, HASHIMOTO Y: Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioolg. Med. Chem. Lett. (1998) 8:1997–2000.
   PubMedGoogle Scholar
• PETTIT GR, LIPPERT JW III, BOYD MR, VERDIER-PINARD P, HAMEL E: Antineoplastic agents 442. Synthesis and biological activities of dioxostatin. Anti-Cancer Drug Des. (2000) 15:361–371.
   Google Scholar
• SHIRAI R, OKABE T, IWASAKI S: Synthesis of comformationally restricted combretastatins. Heterocycles (1997) 46:145–148.
   Google Scholar
• •The first heterocycle-based CA-4 analogues.
   Google Scholar
• WANG L, WOODS KW, LI Q et al.: Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. Med. Chem (2002) 45:1697–1711.
   Google Scholar
• ••A full paper of a series of orally activeheterocycle-based CA-4 analogues.
   Google Scholar
• OHSUMI K, HATANAKA T, FUJITA K et al.: Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues. Bioorg. Med. Chem. Lett. (1998) 8:3153–3158.
   PubMed Web of Science ®Google Scholar
• NAM NH, KIM Y, YOU YJ, HONG DH, KIM HM, AHN BZ: Combretoxazolones: Synthesis, cytotoxicity and antitumor activity. Bioorg. Med. Chem. Lett. (2001) 11:3073–3076.
   PubMedGoogle Scholar
• KIM Y, NAM NH, YOU YJ, AHN BZ: Synthesis and cytotoxicity of 3,4-diary1-2(51-4-furanones. Bioorg. Med. Chem. Lett. (2002) 12:719–722.
   PubMed Web of Science ®Google Scholar
• FLYNN BL, FLYNN GP, HAMEL E, JUNG MK: The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg. Med. Chem. Lett. (2001) 11:2341–2343.
   PubMed Web of Science ®Google Scholar
• FLYNN BL, VERDIER-PINARD P, HAMEL E: A novel palladium-mediated coupling approach to 2,3-disubstituted benzo[b]thiophenes and its application to the synthesis of tubulin binding agents. Org. Lett. (2001) 3:651–654.
   PubMedGoogle Scholar
• BAN WELL MG, FLYNN BL, WILLIS AC, HAMEL E: Synthesis, X-ray crystal structure and tubulin-binding properties of a benzofuran analogue of the potent cytotoxic agent combretastatin A4. Aust.j Chem. (1999) 52:767–774.
   Google Scholar
• TAHIR SK, HAN EKH, CREDO B et al: A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res. (2001) 61:5480–5485.
   PubMedGoogle Scholar
• WU-WONG JR, ALDER JD, ALDER L et al.: Identification and characterization of A-105972, an antineoplastic agent. Cancer Res. (2001) 61:1486–1492.
   PubMed Web of Science ®Google Scholar
• SZCZEPANKIEWICZ BG, LIU G, JAE HS et al.: New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models. Med. Chem. (2001) 44:4416–4430.
   Google Scholar
• LAWRENCE NJ, RENNISON D, WOO M, MCGOWN AT, HADFIELD JA: Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg. Me. Chem. Lett. (2001) 11:51–54.
   PubMedGoogle Scholar
• WOODS KW, MCCROSKEY RW, STEINER BA et al.: Sulfur containing double bond replacement of combretastatin A-4 as antimitotic agents. 221st ACS Meeting. San Diego, USA (2001): MEDI138.
   Google Scholar
• PETTIT GR, TOKI B, HERALD DL et al.: Antineoplastic agents. 379. Synthesis of phenstatin phosphate. j. Med. Chem. (1998) 41:1688–1695.
   Google Scholar
• PETTIT GR, GREALISH MP, HERALD DL, BOYD MR, HAMEL E, PETTIT RK: Antineoplastic agents. 443. Synthesis of the cancer cell growth inhibitor hydroxyphenstatin and its sodium diphosphate prodrug. I Med. Chem. (2000) 43:2731–2737.
   Google Scholar
• ALEKSANDRZAK K, MCGOWN AT, HADFIELD JA: Antimitotic activity of diaryl compounds with structural features resembling combretastatin A-4. Anti-Cancer Drugs (1998) 9:545–550.
   PubMedGoogle Scholar
• GHATAK A, DORSEY J, GARNER CM, MOCHARLA VP CHEN Z, PINNEY KG: Studies in anticancer compounds: synthesis of 6-methoxy-1- (3', 4', 5'-trimethoxypheny1-3,4-dihydronaphthalene further functionalized at C-5 or C-7. 222nd ACS Meeting. Chicago, USA (2001): ORGN153.
   Google Scholar
• DAMAYANTHI Y, LOWN JW: Podophyllotwdns: current status and recent developments. Carr. Med. Chem. (1998) 5:205–252.
   PubMed Web of Science ®Google Scholar
• •A good review of podophyllotoxins before 1998.
   Google Scholar
• LI Q, STEINER BA, WOODS KW et al.: Synthesis and biological evaluation of diarylsulfonamides as tubulin polymerisation inhibitors. Discovery OIA-318315 and A-293620 as orally and intravenously active antitumor agents. 93rd Annual Meeting of American Association for Cancer Research 2002. San hancisco, USA (2002). Abstract 1313.
   Google Scholar
• •A novel series of orally active sulfonamides A-318315 and A–293620.
   Google Scholar
• GWALTNEY SL, II, IMADE HM, LI Q et al.: Novel sulfonate derivatives: potent antimitotic agents. Bioorg. Med. Chem. Lett. (2001) 11:1671–1673.
   PubMedGoogle Scholar
• GWALTNEY SL, II, IMADE HM, BARR KJ et al: Novel sulfonate analogues of combretastatin A-4: Potent antimitotic agents. Bioorg. Med. Chem. Lett. (2001) 11:871–874.
   PubMedGoogle Scholar
• OWA T, NAGASU T: Novel sulphonamide derivatives for the treatment of cancer. Exp. Opin. Ther. Patents (2000) 10:1725–1740.
   Web of Science ®Google Scholar
• •Review on sulfonamides as anticancer agents, including E7010 and E7070.
   Google Scholar
• YOSHIMATSU K, YAMAGUCHI A, YOSHINO H, KOYANAGI N, KITOH K: Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res. (1997) 57:3208–3213.
   PubMed Web of Science ®Google Scholar
• IWAMOTO Y, NISHIO K, FUKUMOTO H, YOSHIMATSU K, YAMAKIDO M, SAIJO N: Preferential binding of E7010 to murine I33-tubulin and decreased I33-tubulin in E7010-resistant cell lines. fpn. I Cancer. Res. (1998) 89:954–962.
   Google Scholar
• ZIELINSKI MOZNY NA, NUKKALA MA, WILSON ST et al: Biological activity of ABT-751: an oral antimitotic agent. 93rd Annual Meeting of American Association for Cancer Research San Francisco, USA (2002): Abstract 1323.
   Google Scholar
• ••Evidence that ABT-751 (E7010) isaccumulated specifically in tumour tissues in vivo with over tenfold higher concentrations in tumours than in plasma.
   Google Scholar
• YOSHINO H, NORIHIRO U, NIIJIMA J et al.: Novel sulfonamides as potential, systemically active antitumor agents. I Med. Chem. (1994) 35:2496–2497.
   Google Scholar
• FUNAHASHI Y, KOYANAGI N, KITOH K: Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor. Cancer Chemother. Pharmacol (2001) 47:179–184.
   PubMed Web of Science ®Google Scholar
• SEGRETI J, POLAKOWSKI J, DIERKS K et al.: Selective effect of the novel anti-mitotic compound ABT-751 on tumor vasculature: an in vivo rat hemodynamic study. 93rd Annual Meeting of American Association for Cancer Research San Francisco, USA (2002): Abstract 783.
   Google Scholar
• •Antivascular effect of E7010 (ABT-751) in viva
   Google Scholar
• LUO Y, MOHNING KM, NUSS ME et al.:A novel anti-tubulin agent (ABT-751) selectively reduces tumour perfusion in a subcutaneous rat tumour model as measured by MRI. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 784.
   Google Scholar
• •Antivascular effect of E7010 (ABT-751) as measured by MRI.
   Google Scholar
• YAMAMOTO K, NODA K, YOSHIMURA A, FUKUOKA M, FURUSE K, NIITANI H: Phase I study of E7010. Cancer Chemother. Pharmacol (1998) 42:127–134.
   PubMed Web of Science ®Google Scholar
• UEDA N, TSUKAHARA N, WATANABE T et al: ER-34410, a structurally novel sulfonamide as a potential injectable antitumor agent. Proc. Am. Assoc. Cancer Res. (1995) 36:Abstract 2290.
   Google Scholar
• KATOH F, HONMURA T, YAMAGUCHI R, MATSUDA M, KIMURA K, HIDAKA H: HMN-214, a novel antitumor sulfonamide compound. Proc. Am. Assoc. Cancer Res. (1997) 38:Abstract 473.
   Google Scholar
• KATOK F, TAKAGI M, KITAZAWA C et al.: Mode of mechanisms of cell death induced by HMN-214, a novel antitumor sulfonamide compound. Proc. Am. Assoc. Cancer Res. (1998) 39:Abstract 225.
   Google Scholar
• TANAKA H, OHSHIMA N, HIKADA H: Apoptosis induction by novel anti-cancer compound, HMN-154 (HMN-176) through suppressing the expression of cell cycle controllers. Proc. Am. Assoc. Cancer Res. (1998) 39:Abstract 319.
   Google Scholar
• TANAKA H, OHSHIMA N, HIDAKA H: Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. Ma Pharmacol (1999) 55:356–363.
   PubMed Web of Science ®Google Scholar
• TAYLOR C, DRAGOVICH T, SIMPSON A, VON HOFF D: A Phase I and pharmakokinetic study of HMN-214 administered orally for 21 consecutive days, repeated every 28 days to patients with advanced solid tumours. 38th Annual Meeting of American Socien, of Clinical Oncology Orlando, USA (2002): Abstract 419.
   Google Scholar
• PATNAIK A, FORERO L, TOLCHER AW et al.: A Phase I and pharmacokinetic (PK) study of HMN-214, an oral antimitotubular agent with polo-like and cyclin-dependent kinase inhibitory activities. 38th Annual Meeting of American Society of Clinical Oncology Orlando, USA (2002): Abstract 418.
   Google Scholar
• WANG HK, XIA Y, YANG ZY, NATSCHKE SL, LEE KH: Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Adv. Expel: Med. Biol. (1998) 439:191–225.
   PubMed Web of Science ®Google Scholar
• •A review of flavonoids before 1998.
   Google Scholar
• BEUTLER JA, HAMEL E, VLIETINCK AJ et al.: Structure-activity requirements for flavone cytotoxicity and binding to tubulin. I Med. Chem. (1998) 41:2333–2338.
   PubMed Web of Science ®Google Scholar
• POBST J, KUFFEL MJ, ARNT CR: Aminoflavone (NSC 686288) induction of vytochrome P450 1A1 in sensitive human cell lines is associated with metabolic activation, DNA damage and antiproliferative activity. Clin. Cancer Res. (2001) 7(Suppl.):3797.
   Google Scholar
• LOAIZA PEREZ Al, VISTICA D, KENNEY S et al.: The aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to the antitumor agent NSC 686288. Clin. Cancer Res. (2001) 7(Suppl.):3737.
   Google Scholar
• BROWN AP, MORRISEY RL, RODVOLD KA et al.: Intravenous plasma elimination kinetics and toxicity of an aminoflavone in the dog. Proc. Am. Assoc. Cancer Res. (1999) 40:Abstract 390.
   Google Scholar
• ALLEY MC, STINSON SF, PACULA COX CM et al.: Pharmacologic evaluations of a novel amino-substiituted flavone (NSC 686288) exhibiting unique M vitro and in vivo anticancer activities. Proc. Am. Assoc Cancer Res. (1999) 40:Abstract 119.
   Google Scholar
• DYKES DJ, HOLLINGSHEAD DJ, CAMALIER RF, MAYO JG, SAUSVILLE EA: Marked activity of an aminoflavone (NSC-686288) against human renal tumors in athymic nude mice. Proc. Am. Assoc. Cancer Res. (1999) 40:Abstract 118.
   Google Scholar
• PIETERS L, VAN DYCK S, GAO M et al: Synthesis and biological evaluation of dihydrobenzofuran lignans and related compounds as potential antitumor agents that inhibit tubulin polymerisation. I Med. Chem. (1999) 42:5475–5481.
   PubMed Web of Science ®Google Scholar
• XIA Y, YANG ZY, MORRIS- NATSCHKE SL, LEE KH: Recent advances in the discovery and development of quinolones and analogs as antitumor agents. Carr. Med. Chem. (1999) 6:179–194.
   PubMedGoogle Scholar
• •A good review of quinolone antiturnour agents, including antimitotic agents, before 1999.
   Google Scholar
• LI L, WANG HK, KUO SC et al.: Antitumor agents. 155. Synthesis and biological evaluation of 3,6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents. I Med. Chem. (1994) 37:3400–3407.
   Google Scholar
• XIA Y, YANG ZY, XIA P et al.: Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents. I Med. Chem. (2001) 44:3932–3936.
   Google Scholar
• •A good summary of quinolone antimitotic agents.
   Google Scholar
• ZHANG SX, BASTOW KF, TACHIBANA Y et al.: Antitumor agents. 196. Substituted 2-thieny1-1,8- naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerisation. I Med. Chem. (1999) 42:4081–4087.
   Google Scholar
• XIA Y, YANG ZY, HOUR MJ et al.: Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg. Med. Chem. Lett. (2001) 11:1193–1196.
   Google Scholar
• HOUR MJ, HUANG LJ, KUO Sc et al: 6-Alkylamino- and 2,3-dihydro-3'-methoxy-2-pheny1-4-quinazolinones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerisation. I Med. Chem. (2000) 43:4479–4487.
   PubMed Web of Science ®Google Scholar
• LI Q, WOODS KW, CLAIBORNE A et al.: Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerisation inhibitors. Discovery of A-289099 as an orally active antitumor agent. Bioorg. Med. Chem. Lett. (2002) 12:465–469.
   Google Scholar
• •SAR leading to a series of orally active oxazoline antimitoic agents (A-289099).
   Google Scholar
• TAHIR SK, NUKKALA MA, ZIELENIEWSKI MOZNY NA et al.: Biological activity of A-289099: an indole-oxazoline derivative with antimitotic activity. 93d Annual Meeting of American Association for Cancer Research San Francisco, USA (2002): Abstract 1315.
   Google Scholar
• ZIELENIEWSKI MOZNY NA, CREDO RB, TAHIR SK et al: Biological efficacy of A-318315: an orally active antimitotic agent. 93d Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002). Abstract 1314.
   Google Scholar
• •In vitro and in vivo activity of A-318315.
   Google Scholar
• MEDARDE M, RAMOS A, CABALLERO E et al.: Synthesis and antineoplastic activity of combretastatin analogues - heterocombretastatins. Ear. Med. Chem. (1998) 33:71–77.
   Web of Science ®Google Scholar
• OWA T, YOSHINO H, OKAUCHI T et al.: Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. Med. Chem. (1999) 42:3789–3799.
   Google Scholar
• •SAR leading to E7070.
   Google Scholar
• FUKUOKA K, USUDA J, IWAMOTO Y et al.: Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest. New Drugs (2001) 19:219–227.
   PubMed Web of Science ®Google Scholar
• OZAWA Y, SUGI NH, NAGASU T et al.: E7070, a novel sulfonamide agent with potent antitumour activity in vitro and M viva Eur. Cancer (2001) 37:2275–2282.
   Web of Science ®Google Scholar
• PUNT CJ, FUMOLEAU P VAN DE WALLE B, FABER MN, RAVIC M, CAMPONE M: Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann. amyl (2001) 12:1289–1293.
   Google Scholar
• VAN KESTEREN C, MATHOT RA, RAYMOND E et al.: Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of the novel anticancer agent E7070 in four Phase I studies. Br. J Clin. Pharmacol (2002) 53:553P.
   Google Scholar
• FUNAHASHI Y, SUGI NH, HANEDA T et al.: Cell and tumor biology 38: angiogenesis inhibitors IV: novel inhibitors. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000). Abstract 4093.
   Google Scholar
• SEMABA T, FUNAHASHI Y, YAMAMOTO Y et al.: A novel angiogenesis inhibitor, ER-68203-00, II. Anti-angiogenesis potency and therapeutic efficacy in tumor xenograf models. 91st Annual Meeting of American Assocbtion for Cancer Research. San Francisco, USA (2000). Abstract 4094.
   Google Scholar
• ONO N, SEMBA T, HOSHI SS et al: Angiogenesis inhibitor, E7820; enhancement of anti-angiogenic activity through the combination with receptor kinase inhibitors of VEGF or BFGF. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002). Abstract 912.
   Google Scholar
• FOTOUHI N, AHMAD M, BANNER B et al.: Synthesis and structure-activity relationship of bis-indolylmaleimides as cell cycle inhibitors: elaboration of the development candidate, Ro 31–7453. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002) Abstract 3655.
   Google Scholar
• •Extensive SAR of a series of indolyl maleimides as tubulin polymerisation inhibitors.
   Google Scholar
• KONG N, SPECIAN JR. A, LOVEY A et al.: Design and synthesis of novel orally bioavailable bisindolyl maleimides as cell cycle inhibitors. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002). Abstract 3656.
   Google Scholar
• RITLAND S, STEELE T, KEN R et al: Preclinical characterization of Ro 31–7453. 92nd Annual Meeting of American Association for Cancer Research; New Orleans, USA (2001). Abstract 4893.
   Google Scholar
• NICOLSON M, BISSET D, CASSIDY J et al.: A Phase I clinical and pharmacokinetic study of oral Ro 31–7453, a novel cell cycle inhibitor, administered in combination with gemcitabine. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 1369.
   Google Scholar
• MEDARDE M, RAMOS AC, CABALLERO E et al: Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg. Med. Chem. Lett. (1999) 9:2303–2308.
   PubMedGoogle Scholar
• GOLDBRUNNER M, LOIDL G, POLOSSEK T, MANNSCHRECK A, VON ANGERER E: Inhibition of tubulin polymerisation by 5,6-dihydroindolo. Med. Chem. (1997) 40:3524–3533.
   Google Scholar
• GASTPAR R, GOLDBRUNNER M, MARKO D, VON ANGERER E: Methoxy-substituted 3-formy1-2-phenylindoles inhibit tubulin polymerisation. I Med. Chem. (1998) 41:4965–4972.
   PubMed Web of Science ®Google Scholar
• MAHBOOBI S, PONGRATZ H, HUFSKY H et al: Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. I Med. Chem. (2001) 44:4535–4553.
   PubMed Web of Science ®Google Scholar
• •A full paper of a series of 2-aroylindoles as tubulin polymerisation inhibitors.
   Google Scholar
• MCGOWN AT, FOX BW: Interaction of the novel agent amphethinile with tubulin. Br. Cancer (1989) 59:865–868.
   Google Scholar
• BACHER G, NICKEL B, EMIG P et al: D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res. (2001) 61:392–399.
   PubMed Web of Science ®Google Scholar
• •In vivo efficacy of D-24951.
   Google Scholar
• NICHEL B, SCHMIDT M, DREVS J et al.: Potent M vivo antitumor activity of D-24851, a novel tubulin inhibitor, in human xenografts and antimetastatic effect in the renca model. 92nd Annual Meeting of American Association for Cancer Research. New Orleanes, USA (2001): Abstract 1992.
   Google Scholar
• GUNTHER E, EMIG P, REICHERT D et al.: Discovery and synthesis of novel N subsituted indoly1-3-glyoxylic acid derivatives with tubulin-binding activity as anticancer agents. 91st Annual Meeting of American Association for Cancer Research San Francisco, USA (2000). Abstract 4888.
   Google Scholar
• MEDINA JC, SHAN B, BECKMANN H et al.: Novel Antineoplastic agents with efficacy against multidrug resistant tumour cells. Bioorg. Med. Chem. Lett. (1998) 8:2653–2656.
   PubMed Web of Science ®Google Scholar
• YE Q, FRANKMOELLE W, LE H, WRIGHT R, TIMMERMANS PB: Identification and detection of T138067 metabolites formed in vitro in the presence of rat hepatic subcellular fractions and in vivo in humans. 91st Annual Meeting of American Association for Cancer Research San Francisco, USA (2000): Abstract 1380.
   Google Scholar
• SHAN B, MEDINA JC, SANTHA E et al.: Selective, covalent modification of 13-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proc. Nati Acad. Sri. USA (1999) 96:5686–5691.
   PubMed Web of Science ®Google Scholar
• MEDINA JC, ROCHE D, SHAN B et al.: Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells. Bioorg. Med. Chem. Lett. (1999) 9:1843–1846.
   PubMed Web of Science ®Google Scholar
• •T138067 SAR.
   Google Scholar
• FRANKMOELLE WP, MEDINA JC, SHAN B, NARBUT MR, BECKMANN H: Glutathione S-transferase metabolism of the antineoplastic pentafluorophenylsulfonamide in tissue culture and mice. Drug Metabolism Disposition (2000) 28:951–958.
   PubMedGoogle Scholar
• MOLPUSK, SCHWARTZ G, O'DWYER P et al.: A Phase I study of anti-microtubule agent T138067-sodium administered daily x 5 every 3 weeks. 38th Annual Meeting of American Society of Clinical Oncology Orlando, USA (2002): Abstract 415.
   Google Scholar
• LEUNG TWT, FEUN L, POSEY J, STAGG RJ, LEVY MD, VENOOK AP: A Phase II study of T138067-sodium in patients (pts) with uru-esectable hepatocellular carcinoma. 38th Annual Meeting of American Society of Clinical Oncology Orlando, USA (2002): Abstract 572.
   Google Scholar
• JAHAN TM, SANDLER A, BURRIS H et aL: A Phase II study T138067-sodium in prior taxane-treated patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSVLC). 38th Annual Meeting of American Society of Clinical Oncology Orlando, USA (2002): Abstract 1282.
   Google Scholar
• BECKMANN H, SANTHA E, LADD A, PARK A, HOUZE J, BAICHWAL V: Selective, covalent modification of certain 13-tubulin isotypes by T900607, a novel antitumor agent with efficacy against multidrug resistant tumors. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 1920.
   Google Scholar
• SCHWENDER SW, HOFFMAN LA, THOOLEN MJ, CHOU TC, TIMMERMANS PB: Efficacy of the novel tubulin binding agent, T900607, against human tumor xenografts in mice. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 1919.
   Google Scholar
• SCHWENDER SW, HOFFMAN LA, THOOLEN MJ, TIMMERMANS PB: Efficacy of combination therapy with the tubulin binding agent, T900607, aaginst MX-1 human mammary tunor xenografts in mice. 91st Annual Meeting of American Association for Cancer Research San Francisco, USA (2000): Abstract 1914.
   Google Scholar
• WRIGHT MR, YE Q, THOOLEN MJ, KYNCH HD, STEIN CK, TIMMERMANS PB: Pharmacokinetics of T900607 in preclinical species. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 1921.
   Google Scholar
• CASSIDY J, KILLHAM P, ASIF-SULEMAN S, GIORDANO H, LEVY M, CARMICHAEL J: A Phase I study of T900607-sodium administered weekly in patients with refractory cancer. 38th Annual Meeting of American Society of Clinical Oncology Orlando, USA (2002): Abstract 416.
   Google Scholar
• LOCKHART AC, MANI S, OLSEN R et al.: T900607-sodium administered daily x 5 as a 60-minute infusion every 3 weeks: a Phase I studt of T900607-sodium in patients (pts) with refractory cancer. 38th Annual Meeting of American Society of Clinical Oncology Orlando, USA (2002): Abstract 417.
   Google Scholar
• MEDINA JC, DEXTER DW, BAICHWAL V et al.: Efficacy of T138067 and its analogs against resistant tumor cells that express the MDR1 drug pump, have mutation on I3-tubulin, or changes in 13-tubulin isotype expression patterns. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 1378.
   Google Scholar
• RUBENSTEIN SM, BAICHWAL V, BECKMANN H et al.: Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. Med. Chem. (2001) 44:3599–3605.
   Google Scholar
• LEGAULT J, JEAN-FRANCOIS G, MOUNETOU E et al: Microtubule distribution induced in vivo by alkylating of 13-tubulin by 1 -aryl -3- (2 chloroethyl)ureas, a novel class of soft alkylating agents. Cancer Res. (2000) 60:985–992.
   PubMedGoogle Scholar
• MOUNETOU E, LEGAULT J, LACROIX J, R CG: Antimitotic antitumor agents: synthesis, structure-activity relationships, and biological characterization of N-aryl-N-(2-chloroethyl)ureas as new selective alkylating agents. j Med. Chem. (2001) 44:694–702.
   PubMed Web of Science ®Google Scholar
• JIANG JD, DAVIS AS, MIDDLETON K et al.: 3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerisation, phosphorylates bc1-2, and induces apoptosis in tumor cells. Cancer Res. (1998) 58:5389–5395.
   PubMed Web of Science ®Google Scholar
• JIANG JD, WANG Y, ROBOZ J, STRAUCHEN J, HOLLAND JF, BEKESI JG: Inhibition of microtubule assembly in tumour cells by 3-bromoacetylamino benzoyurea, a new cancericidal compound. Cancer Res. (1998) 58:2126–2133.
   PubMedGoogle Scholar
• PINNEY KG, BOUNDS AD, DINGEMAN KM et al.: A new anti-tubulin agent containing the benzo[b]thiophene ring system. Bioorg. Med. Chem. Lett. (1999) 9:1081–1086.
   PubMedGoogle Scholar
• •The first paper on benzothiophene based tubulin polymerisation, which lead to the discovery of the most potent indole series.
   Google Scholar
• CHEN Z, MOCHARLA VP, FARMER JM, PETTIT GR, HAMEL E, PINNEY KG: Preparation of new anti-tubulin ligands through a dual-mode, addition-elimination reaction to a bromo-substituted a, 13-unsaturated sulfoxide. Org. Chem. (2000) 65:8811–8815.
   PubMedGoogle Scholar
• MULLICA DF, PINNEY KG, MOCHARLA VP, DINGEMAN KM, BOUNDS AD, SAPPENFILED EL: Characterization and structural analyses of trimethoxy and triethoxybenzo[b]thiophene. I Chem. Crystallography (1998) 28:289–295.
   Google Scholar
• PEYROT V, LEYNADIER D, SARRAZIN M et al: Mechanism of binding of the new antimitotic drug MDL 27048 to the colchicine site of tubulin: equilibrium studies. Biochem. (1992) 31:11125–11132.
   PubMed Web of Science ®Google Scholar
• DUCKI S, FORREST R, HADFIELD JA et al.:Potent antimitotic and cell growth inhibitory properties of substituted chalcones. Bioorg. Med. Chem. Lett. (1998) 8:1051–1056.
   PubMed Web of Science ®Google Scholar
• •Incorporating the structural features of CA-4 to charlcones.
   Google Scholar
• LAWRENCE NJ, MCGOWN AT, DUCKI S, HADFIELD JA: The interaction of chalcones with tubulin. Anti-Cancer Drug Des. (2000) 15:135–141.
   PubMedGoogle Scholar
• XIA Y, YANG Z, XIA P, BASTOW KF, NAKANISHI Y, LEE KH: Antitumor agents. Part 202: novel 2'-amino chalcones: design, synthesis and biological evaluation. Bioorg. Med. Chem. Lett. (2000) 10:699–701.
   Google Scholar
• TATSUMI Y, ARIOKA H, IKEDA Set al: Enhancement of in vivo antitumor activity of a novel antimitotic 1-phenylpropenone derivative, AM-132, by tumor necrosis factor-alpha or interleukin-6. fpn. I Cancer Res. (2001) 92:768–777.
   Google Scholar
• •Indole-containing charlcones SAR and AM-132.
   Google Scholar
• KANOH K, KOHNO S, ASARI T et al.: O-Phenylahistin - a new mammalian cell cycle inhibitor produced by Aspergiilus ustus. Biooig. Med. Chem. Lett. (1997) 7:2847–2852
   Web of Science ®Google Scholar
• KANOH K, KOHNO S, KATADA J, HAYASHI Y, MURAMATSU M, UNO I: Antitumor activity of phenylahistin in vitro and M vivo. Biosci. Biotechnol. Biochem. (1999) 63:1130–1133.
   PubMed Web of Science ®Google Scholar
• KANOH K, KOHNO S, KATADA J, TAKAHASHI J, UNO I: (-)-Phenylahistin arrests cells in mitosis by inhibiting tubulin polymerisation. Antibiot. (1999) 52:134–141.
   Google Scholar
• KANOH K, KOHNO S, KATADA J, TAKAHASHI J, UNO I, HAYASHI Y: Synthesis and biological activities of phenylahistin derivatives. Bioorg. Med. Chem. (1999) 7:1451–1457.
   PubMed Web of Science ®Google Scholar
• •SAR of halimide derivatives.
   Google Scholar
• HAYASHI Y, ORIKASA S, TANAKA K, KANOH K, KISO Y: Total synthesis of anti-microtubule diketopiperazine derivatives: phenylahistin and aurantiamine. J. Org. Chem. (2000) 65:8402–8405.
   PubMedGoogle Scholar
• USUI T, KONFOH M, CUI C, MAYUMI T, OSADA H: Tryprostatin A, a specific and novel inhibitor of microtubule assembly. Biochem. J. (1998) 333:543–548.
   PubMed Web of Science ®Google Scholar
• SANZ-CERVERA JF, STOCKING EM, USUI T, OSADA H, WILLIAMS PM: Synthesis and evaluation of microtubule assembly inhibition and cytotoxicity of prenylated derivatives of cyck-L-Trp-L-Pro. Bioorg. Med. Chem. (2000) 8:2407–2415.
   PubMed Web of Science ®Google Scholar
• ZHAO S, SMITH KS, DEVEAU AM et al: Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines.' Med. Chem. (2002) 45:1559–1562.
   Google Scholar
• •Provides a brief summary of the tryprostatin related diketopiperazine compounds.
   Google Scholar
• GOLUBOFF ET: Exisulind, a selective apoptotic antineoplastic drug. Exp. Opin. Invest. Drugs (2001) 10:1875–1882.
   PubMedGoogle Scholar
• BUNN PA Jr, CHAN DC, EARLE K et al: Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin. Oncol. (2002) 29:87–94.
   PubMedGoogle Scholar
• THOMPSON WJ, PIAZZA GA, LI H et al.: Eidsulind induction of apoptosis involves guanosine 3, 5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. (2000) 60:3338–3342.
   PubMed Web of Science ®Google Scholar
• SOH JVV, MAO Y, KIM MG et al: Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin. Cancer Res. (2000) 6:4136–4141.
   PubMedGoogle Scholar
• FETTER JR, WHITEHEAD C, YOON J-T et al.: G2/M cell cycle arrest by the pro-apoptotic cGMP phosphodiesterase inhibitor, CP248, in 5W480 colon cancer cells involves inhibition of tubulin polymerisation via the colchicine binding site. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002). Abstract 1319.
   Google Scholar
• •Activity of CP248 and tubulin polymerisation activity.
   Google Scholar
• LIM JT, PIAZZA GA, HAN EK et at.: Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem. Pharmacol. (1999) 58:1097–1107.
   Google Scholar
• LISOWSKI V, ENGUEHARD C, LANCELOT J et al.: Design, synthesis and antiproliferative activity of tripentones: a new series of antitubulin agents. Bioorg. Med. Chem. Lett. (2001) 11:2205–2208.
   PubMedGoogle Scholar
• •A novel series of potent CA-4 anlogues with the A ring replaced by tripentones.
   Google Scholar
• CHEN X, PINE P, KNAPP AM, TUSE D, LADEROUTE KR: Oncocidin Al: a novel tubulin-binding drug with antitumor activity against human breast and ovarian carcinoma xenografts in nude mice. Biochem. Pharmacol. (1998) 56:623–633.
   PubMedGoogle Scholar
• KUN E, MENDELEYEV J: Molecular pharmacology of methyl-3,5-diiodo-4 (4'-methoxyphenoxy) benzoate (DIME) and its non-hydrolyzible ethanone analog (DIPE) (Review). Int. I Mol. Med. (1998) 2:585–590.
   PubMedGoogle Scholar
• SHAN SQ, LOCKHART AC, SAITO WY, KNAPP AM, LADEROUTE KR, DEWHIRST MW: The novel tubulin-binding drug BTO-956 inhibits R3230Ac mammary carcinoma growth and angiogenesis in Fischer 344 rats. Clin. Cancer Res. (2001) 7:2590–2596.
   PubMed Web of Science ®Google Scholar
• NAITO H, SUGIMORI M, MITSUI I et al.: Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. Chem. Pharm. Bull. (Tokyo) (1999) 47:1679–1684.
   PubMedGoogle Scholar
• IWAHANA M, OCHI Y, EJIMA A: Antiproliferative activity and mechanism of action of DZ-3358, a novel pyrimidinyl pyrazole derivative. Anticancer Res. (2000) 20:785–792.
   PubMedGoogle Scholar
• NAITO H, OHSUKI S, SUGIMORI M et al.: Synthesis and antitumor activity of novel pyrimidinyl pyrazole derivatives. II. optimisation of the phenylpiperazine moiety of 145-methyl 1 (2 pyrimidiny1)-4-pyrazoly11-3-phenylpiperaziny1-1-trans-propenes. Chem. Pharm. Bull. (Tokyo) (2002) 50:453–462.
   Google Scholar
• GUNTHER EG, EMIG P, BAASNER S, SCHMIDT P, AUE B, POLYMEROPOULOS E: 1-Pheny1-4-piperazinyl-carbonyl-substituted heterocyclic derivatives-a new class of highly potent compounds with inhibitory efffects on the tubulin polymerisation. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002) Abstract 3654.
   Google Scholar
• •Extensive SAR of the novel tubulin polymerisation inhibitor D-82318.
   Google Scholar
• DE INES C, LEYNADIER D, BARASOAIN I et at Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dihydropteridine antitumor drug, CI 980, and by its chiral isomer, NSC 613863. Cancer Res. (1994) 54:75–84.
   PubMed Web of Science ®Google Scholar
• ROWINSKY EK, LONG GS, NOE DA et al.: Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clin. Cancer Res. (1997) 3:401–407.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN ML, BARUCHEL S, DEVINE S et al.: Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. I Pediatr. Hematol. Omni (1999) 21:494–500.
   Web of Science ®Google Scholar
• SKLARIN NT, LATHIA CD, BENSON L et al.: A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Invest. New Drugs (1997) 15:235–246.
   PubMed Web of Science ®Google Scholar
• THOMAS JP, MOORE T, KRAUT EH, BALCERZAK SP, GALLOWAY S, VANDRE DD: A phase II study of CI-980 in previously untreated extensive small cell 1698 lung cancer: an Ohio State University phase II research consortium study. Cancer Invest. (2002) 20:192–198.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD RP UNGER JM, FLAHERTY LE et al.: Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Invest. New Drugs (2001) 19:239–243.
   Google Scholar
• PATEL SR, BURGESS MA, PAPADOPOLOUS NE et al: Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Invest. New Drugs (1998) 16:87–92.
   PubMed Web of Science ®Google Scholar
• KUDELKA PP, HASENBURG A, VERSCHRAEGEN CF et al.: Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs (1998) 9:405–409.
   Google Scholar
• PAZDUR R, MEYERS C, DIAZ-CANTON E et al.: Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. Am. Oncol (1997) 20:573–576.
   Google Scholar
• IMBERT TF: Discovery of podophyllotoxins. Biochlin. (1998) 80:207–222.
   Google Scholar
• VERDIER-PINARD P, LAI JY, Y00 HD et al.: Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol. Pharmacol (1998) 53:62–76.
   Google Scholar
• VERDIER-PINARD P, SITACHITTA N, ROSSI JV, SACKETT DL, GERWICK WH, HAMEL E: Biosynthesis of radiolabeled curacin A and its rapid and apparently irreversible binding to the colchicine site of tubulin. Arch. Biochem. Biophy. (1999) 370:51–58.
   PubMed Web of Science ®Google Scholar
• WIPE P, REEVES JT, BALACHANDRAN R, DAY BW: Synthesis and biological evaluation of structurally highly modified analogues of the antimitotic natural product curacin A. Med. Chem. (2002) 45:1901–1917.
   Google Scholar
• •SAR of curacin A analogues and a good summary of curacin A literature.
   Google Scholar
• COMBEAU C, PROVOST J, LANCELIN F et al: RPR112378 and RPR115781: two representatives of a new family of microtubule assembly inhibitors. MM. Pharmacol (2000) 57:553–563.
   PubMedGoogle Scholar
• CUSHMAN M, HE HM, KATZENELLENBOGEN JA, UN CM, HAMEL E: Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerisation by binding to the colchicine binding site. I Med. Chem. (1995) 38:2041–2049.
   PubMed Web of Science ®Google Scholar
• MILLER TA, BULMAN AL, THOMPSON CD, GARST ME, MACDONALD TL: Synthesis and structure-activity profiles of A-homoestranes, the estratropones. I Med. Chem. (1997) 40:3836–3841.
   PubMedGoogle Scholar
• CUSHMAN M, HE HM, KATZENELLENBOGEN JA et al.: Synthesis of analogs of 2-methoxyestradiol with enhanced inhibitory effects on tubulin polymerisation and cancer cell growth. .1 Med. Chem. (1997) 40:2323–2334.
   Google Scholar
• WANG Z, YANG D, MOHANAKRISHNAN AK et al.: Synthesis of B ring homologated estradiol analogues that modulate tubulin polymerisation and microtubule stability. Med. Chem. (2000) 43:2419–2429.
   Google Scholar
• NICHOLSON KM, PHILLIPS RIVI, SHNYDER SD, BIBBY MC: In vitro and M vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine. Eur. Cancer (2002) 38:194–204.
   PubMedGoogle Scholar
• •Structure based design using estrarnustine leading to a series of the biphenyl antimitoic agents.
   Google Scholar
• HILL BT: Vinflunine, a second generation novel Vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr. Pharm. Des. (2001) 7:1199–1212.
   PubMedGoogle Scholar
• LOBERT S, CORREIA JJ: Energetics of Vinca alkaloid interactions with tubulin. Methods Enzymol (2000) 323:77–103.
   PubMedGoogle Scholar
• SHIH C, TEICHER BA: Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides. Curr. Pharm. Des. (2001) 7:1259–1276.
   PubMed Web of Science ®Google Scholar
• •A review of cryptophycins.
   Google Scholar
• ROWINSKY EK, DONEHOWER RC: Antimitotic agents. In: Cancer: Principles and Practice of Oncology DeVita VT, Hellman S, Rosenberg SA (Eds), Lippincott-Raven, Philadelphia (1997):468–472.
   Google Scholar
• •SAR, clinical usage, pharmacology, and toxicity of the Vinca alkaloids and taxanes.
   Google Scholar
• FAHY J: Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curt: Pharm. Des. (2001) 7:1181–1197.
   Google Scholar
• •A review of modifications of the catharanthine motif of the Vinca alkaloids.
   Google Scholar
• GREGORY RK, SMITH I: Vinorelbine-a clinical review. Br. Cancer (2000) 82:1907–1913.
   Google Scholar
• SCHWARTZ GN, BONG D, LEICHMAN CG, LEICHMAN LL: Phase I evaluation of anhydrovinblastine in patients with advanced malignancies. 91st Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000): Abstract 3895.
   Google Scholar
• RAMNATH N, SCHWARTZ GN, BOOKER B et al: A Phase land pharmacokinetic study of anhydrovinblastine. 38th Annual Meeting of American Socieo, of Clinical Oncology Orlando, USA (2002): Abstract 421.
   Google Scholar
• KRUCZYNSKI A, HILL BT: Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Critical Rev Oncology-Hematology (2001) 40:159–173.
   PubMed Web of Science ®Google Scholar
• LOBERT S, INGRAM JW, HILL BT, CORREIA JJ: A comparison of thermodynamic parameters for vinorelbine-and vinflunine-induced tubulin self-association by sedimentation velocity. Mol. Pharmacol. (1998) 53:908–915.
   PubMed Web of Science ®Google Scholar
• FUMOLEAU P, RAYMOND E, BENNOUNAJ et al: Phase I trial of vinflunine (L0070) a novel fluorinated Vinca alkaloid in patients (pts) with advanced solid malignancies: final results. 92nd Annual Meeting of American Association for Cancer Research. Orlando, USA (2001): Abstract 4478.
   Google Scholar
• KRUCZYNSKI A, RICOME C, ASTRUC J et al.: Significant antiangiogenic activity and marked inhibition of growth of an orthotopic colon cancer model and colon liver metastases by vinflunine, the most recent Vinca alkaloid in clinical development. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002): Abstract 1332.
   Google Scholar
• COMIN-ANDUIX B, AGELL N, BACHS O, OVADI J, CASCANTE M: A new bis-indole, KARs, induces selective M arrest with specific spindle aberration in neuroblastoma cell line SH-SY5Y. Mal Pharmacol (2001) 60:1235–1242.
   PubMedGoogle Scholar
• CORBETT TH, VALERIOTE FA, DEMCHIK L et al.: Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice. Invest. New Drugs(1997) 15:207–218.
   PubMedGoogle Scholar
• PANDA D, DELUCA K, WILLIAMS D, JORDAN MA, WILSON L: Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc. Natl. Acad. Sd. USA (1998) 95:9313–9318.
   PubMed Web of Science ®Google Scholar
• PANDA D, ANANTHNARAYAN V, LARSON G, SHIH C, JORDAN MA, WILSON L: Interaction of the antitumor compound cryptophycin-52 with tubulin. Biochem. (2000) 39:14121–14127.
   PubMed Web of Science ®Google Scholar
• LU K, DEMPSEY J, SCHULTZ RM, SHIH C, TEICHER BA: Cryptophycin-induced hyperphosphorylation of Bc1-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells. Cancer Chemother. Pharmacol. (2001) 47:170–178.
   PubMedGoogle Scholar
• •Phosphorylation and inactivation of BCL-2 by certain antimitotic agents.
   Google Scholar
• EGGEN M, GEORG GI: The cryptophycins: their synthesis and anticancer activity. Med. Res. Rev (2002) 22:85–101.
   PubMedGoogle Scholar
• ••A review of the SAR of cryptophycins.
   Google Scholar
• GOTH G, SCHOTT K, OHNMACHT U, MANEGOLD C, GATZEMEIER U: A Phase II study of LY355703 (cryptophycin) as first-line therapy for stage Mb or IV NCSLC subjects: preliminary analysis. Eur: j Cancer (2001) 37:S48.
   Google Scholar
• HAUSNER PF, EDELMAN MJ, DESANTO J, DOYLE LA, GRANDARA DR, ISRAEL V: Salvage therapy with cryptophycin-52 (C52) in platinum-treated non-small cell lung cancer (NSCLC). 38th Annual Meeting of American Society of Clinical Oncology Orlando, USA (2002): Abstract 2688.
   Google Scholar
• MUNRO MH, BLUNT JW, DUMDEI EJ et al.: The discovery and development of marine compounds with pharmaceutical potential. J. Biotechnol. (1999) 70:15–25.
   PubMed Web of Science ®Google Scholar
• TOWLE MJ, SALVATO KA, BUDROW J et al.: In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. (2001) 61:1013–1021.
   PubMed Web of Science ®Google Scholar
• • Discovery of ER-076349 and ER086526 that show profound in vivo efficacy.
   Google Scholar
• TOWLE MJ, SALVATO KA, BUDROW J et al.: In vivo anticancer activity of synthetic halichondrin B macrocyclic ketone analogs ER-076349 and ER-086526 correlates with ability to induce irreversible mitotic blocks. 92nd Annual Meeting of American Association for Cancer Research. New Orleans, USA (2001). Abstract 1976.
   Google Scholar
• VEDEJS E, KONGKITTINGAM C: A total synthesis of O-hemiasterlin using N-Bts methodology. I Org. Chem. (2001) 66:7355–7364.
   PubMedGoogle Scholar
• •A brief summary of the naturally occurring hemiasterlin tripeptides.
   Google Scholar
• GAMBLE WR, DURSO NA, FULLER RW et al: Cytotoxic and tubulin-interactive hemiasterlins from Auletta sp. and Siphonochalinaspp. sponges. Bioorg. Med. Chem. (1999) 7:1611–1615.
   PubMed Web of Science ®Google Scholar
• BAI R, DURSO NA, SACKETT DL, HAMEL E: Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochem. (1999) 38:14302–14310.
   PubMed Web of Science ®Google Scholar
• ZASK A, BIRNBURG G, CHEUNG K et al.: Synthesis and biogical activity of analogs of the antimicrotubule agent HTI-286. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002):Abstract 3653.
   Google Scholar
• •SAR of HTI-286 analogues.
   Google Scholar
• LOGANZO F, DISCAFANI C, ANNABLE T et al: HTI-286, a synthetic analog of the antimicrotubule tripeptide hemiasterlin, potently inhibits growth of cultured tumor cells, overcomes resistance to paclitaxel mediated by various mechanisms, and demonstrates intravenous and oral in vivo efficacy. 93rd Annual Meeting of American Association for Cancer Research San Francisco, USA (2002):Abstract 1316.
   Google Scholar
• PONCET J: The dolastatins, a family of promising antineoplastic agents. Curr. Pharm. Des. (1999) 5:139–162.
   PubMed Web of Science ®Google Scholar
• ••A review of dalostatins.
   Google Scholar
• KALEMKERIAN GP, OU X, ADIL MR et al: Activity of dolastatin 10 against small-cell lung cancer M vitro and in vivo: induction of apoptosis and bc1-2 modification. Cancer Chemother. Pharmacol. (1999) 43:507–515.
   PubMed Web of Science ®Google Scholar
• WATANABE J, NATSUME T, PITO N, MIYASAKA K, KOBAYASHI M: Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis (2000) 5:345–353.
   PubMed Web of Science ®Google Scholar
• AHERNE GW, HARDCASTLE A, VALENTI M et al: Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay. Cancer Chemother. Pharmacol. (1996) 38:225–232.
   PubMed Web of Science ®Google Scholar
• TOPPMEYER DL, SLAPAK CA, CROOP J, KUFE DW: Role of P-glycoprotein in dolastatin 10 resistance. Biochem. Pharmacol. (1994) 48:609–612.
   PubMed Web of Science ®Google Scholar
• THAMM DH, MACE WEN EG, PHILLIPS BS et al: Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia. Cancer Chemother. Pharmacol. (2002) 49:251–255.
   PubMedGoogle Scholar
• WRIGHT JJ, BLATNER G, CHESON BD: Clinical trials referral resource. Clinical trials of dolastatin-10. Oncol. (Huntington) (1999) 13:68–70.
   PubMedGoogle Scholar
• KRUG LM, MILLER VA, KALEMKERIAN GP et al.: Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer. Annals Oncol. (2000) 11:227–228.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO N, ANDOH M, KAWAHARA M, FUKUOKA M, NIITANI H: Phase I study of TZT-1027, an inhibitor of tubulin polymerisation, given weekly x 3 as a 1-hour intravenous infusion in patients (PTS) with solid tumors. 38th Annual Meeting of American Society of Clinical Oncology Orlando, USA (2002):Abstract 420.
   Google Scholar
• HORTI J: Preliminary result of a Phase I trial of TZT-1027, an inhibitor of tubulin polymerisation, in patients with advanced non-small cell lung cancer. 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002) Abstract 2744.
   Google Scholar
• NO AUTHORS LISTED: TZT-1027. Drugs Fut. (1999) 24:404–409.
   Google Scholar
• HU MK, HUANG WS: Synthesis and cytostatic properties of structure-simplified analogs of dolastatin 15.1 Peptide Res. (1999) 54:460–467.
   PubMedGoogle Scholar
• DE ARRUDA M, COCCHIARO CA, NELSON CM et al: LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res. (1995) 55:3085–3092.
   PubMed Web of Science ®Google Scholar
• SMYTH J, BONETERRE ME, SCHELLENS J et al.: Activity of the dolastatin analogue, LU103793, in malignant melanoma. Ann. Oncol. (2001) 12:509–511.
   PubMed Web of Science ®Google Scholar
• NELSON CM, CONLON D, SMITH PA et al.: Preclinical pharmacology of LU223651, orally available analog of cemadotin HC1. 90st Annual Meeting of American Association for Cancer Research Philadelphia, USA (1999):Abstract 1908.
   Google Scholar
• NICOLETTI MI, TURATTO M, MARTINELLI M, BARLOZZARI T, GIAVAZZI R: Oral antitumor activity of dalastatin 15 analog, LU223651, against
   Google Scholar
• MICHAELSON MD, RYAN DP, FRAM R et al.: A Phase I clinical trial of ILX651, a dolastatin-15 analog, administered as a 30-minute intravenous infusion every other day x 3 doses every 21 days in patients with advanced solid tumors. 38th Annual Meeting of American Association of Clinical Research. Orlando, USA (2002):Abstract 414.
   Google Scholar
• EBBINGHAUS SW, DUNN H, JENNINGS L, DIJK SV, FRAM R: A Phase I and pharmacokineric study of the dolastatin 15 analog ILX651. 38th Annual Meeting of American Association of Clinical Research. Orlando, USA (2002):Abstract 1743.
   Google Scholar
• YE K, KE Y, KESHAVA N et al.: Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc. Natl Acad. Sci. USA (1998) 95:1601–1606.
   PubMed Web of Science ®Google Scholar
• YE K, ZHOU J, LANDEN JW, BRADBURY EM, JOSHI HC: Sustained activation of p34(cdc2) is required for noscapine-induced apoptosis. j Biol. Chem. (2001) 276:46697–46700.
   PubMedGoogle Scholar
• SCHULER M, MUEHLBAUER P, GUZZIE P, EASTMOND DA: Noscapine hydrochloride disrupts the mitotic spindle in mammalian cells and induces aneuploidy as well as polyploidy in cultured human lymphocytes. Mutagenesis (1999) 14:51–56.
   PubMedGoogle Scholar
• LANDEN JW, ARCHER DR, DAVIS TP, WALNER BH, JOSHI HC: The microtubule inhibitor noscapine for the treatment of glioblastoma in immunodefficient mice. 92nd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2000):Abstract 1361.
   Google Scholar
• CHANG Y-T, WIGNALL SM, ROSANIA GR et at Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. j. Med. Chem. (2001) 44:4497–4500.
   PubMedGoogle Scholar
• •SAR of myoservin analogues.
   Google Scholar
• ROSANIA GR, CHANG Y-T, PEREZ O et al.: Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat. Biotechnol (2000) 18:304–308.
   PubMedGoogle Scholar
• UCKUN FM: Rationally designed anti-mitotic agents with pro-apoptotic activity. Carr: Pharm. Des. (2001) 7:1627–1639.
   PubMedGoogle Scholar
• ••A review of the discovery of SPIKET-P andCOBRA-1 by structure based design.
   Google Scholar
• UCKUN FM, MAO C, JAN ST et al.: Spongistatins as tubulin targeting agents. Carr. Pharm. Des. (2001) 7:1291–1296.
   PubMedGoogle Scholar
• JAN ST, MAO C, VASSILEV AO, NAVARA CS, UCKUN FM: COBRA-1, a rationally-designed epoxy-THF containing compound with potent tubulin depolymerising activity as a novel anticancer agent. Bioorg. Med. Chem. Lett. (2000) 10:1193–1197.
   PubMedGoogle Scholar
• FLORSHEIMER A, ALTMANN KH: Epothilones and their analogues - a new class of promising microtubule inhibitors. Exp.Opin. Ther. Patents (2001) 11:951–968.
   Web of Science ®Google Scholar
• JORDAN MA, TOSO RJ, THROWER D, WILSON L: Mechanism of mitotic blockand inhibition of cell proliferation by taxolat low concentrations. Proc. Natl. Acad. Sci. USA (1993) 90:9552–9556.
   PubMed Web of Science ®Google Scholar
• BERGNES G, HA ED, FENG B et al.: Mitotic kinesin-targeted antitumour agents: discovery, lead optimisation and anti-tumor activity of a series of novel quinazolinones as inhibitors of kinesin spindle protein (KSP). 93rd Annual Meeting of American Association for Cancer Research. San Francisco, USA (2002):Abstract 3648.
   Google Scholar
• ••Evidence that paclitaxel is accumulatedinside tumour cells in vitro, with up to a 600-fold higher intracellular uptake. (2002):Abstract 3648.
   Google Scholar
• ••A novel series of antimitotic agents thattarget the motor protein KSP (SB-715992).
   Google Scholar
• JOHNSON RK, MCCABE FL, CAUDER E et al: SB-715992, a potent and selective inhibitor of KSP mitotic kinesin, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. 93rd Annual Meeting of American Association for Cancer Research. San Baum:cm, USA (2002):Abstract 1335.
   Google Scholar
• •See also related abstracts #325, 1336, 1337, 3300 and 5375.
   Google Scholar